- Home
- ATHE vs JAGX Comparison
ATHE vs JAGX Comparison
Compare ATHE & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATHE
- JAGX
- Stock Information
- Founded
- ATHE 1997
- JAGX 2013
- Country
- ATHE Australia
- JAGX United States
- Employees
- ATHE N/A
- JAGX 49
- Industry
- ATHE Biotechnology: Pharmaceutical Preparations
- JAGX Biotechnology: Pharmaceutical Preparations
- Sector
- ATHE Health Care
- JAGX Health Care
- Exchange
- ATHE Nasdaq
- JAGX Nasdaq
- Market Cap
- ATHE 10.1M
- JAGX 10.9M
- IPO Year
- ATHE N/A
- JAGX N/A
- Fundamental
- Price
- ATHE $2.20
- JAGX $0.93
- Analyst Decision
- ATHE Strong Buy
- JAGX
- Analyst Count
- ATHE 2
- JAGX 0
- Target Price
- ATHE $6.00
- JAGX N/A
- AVG Volume (30 Days)
- ATHE 121.1K
- JAGX 538.8K
- Earning Date
- ATHE 02-15-2025
- JAGX 11-13-2024
- Dividend Yield
- ATHE N/A
- JAGX N/A
- EPS Growth
- ATHE N/A
- JAGX N/A
- EPS
- ATHE N/A
- JAGX N/A
- Revenue
- ATHE $2,681,669.00
- JAGX $10,480,000.00
- Revenue This Year
- ATHE N/A
- JAGX $18.18
- Revenue Next Year
- ATHE N/A
- JAGX $40.06
- P/E Ratio
- ATHE N/A
- JAGX N/A
- Revenue Growth
- ATHE 2.63
- JAGX N/A
- 52 Week Low
- ATHE $1.00
- JAGX $0.84
- 52 Week High
- ATHE $3.19
- JAGX $21.60
- Technical
- Relative Strength Index (RSI)
- ATHE 64.85
- JAGX 45.55
- Support Level
- ATHE $2.04
- JAGX $0.85
- Resistance Level
- ATHE $2.45
- JAGX $1.29
- Average True Range (ATR)
- ATHE 0.23
- JAGX 0.09
- MACD
- ATHE -0.00
- JAGX -0.01
- Stochastic Oscillator
- ATHE 71.15
- JAGX 18.27
About ATHE Alterity Therapeutics Limited
Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has a drug candidate for Parkinson's disease and other movement disorders (ATH434). The Group operated in one segment, being researching and developing Parkinsonian and other neurodegenerative disorders.
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.